Next Article in Journal
New Invertebrate Vectors for PST, Spirolides and Okadaic Acid in the North Atlantic
Next Article in Special Issue
Oxygenated Polyketides from Plakinastrella mamillaris as a New Chemotype of PXR Agonists
Previous Article in Journal
Effect of Astaxanthin on Human Sperm Capacitation
Previous Article in Special Issue
Cytotoxic and Anti-Inflammatory Metabolites from the Soft Coral Scleronephthya gracillimum
Mar. Drugs 2013, 11(6), 1920-1935; doi:10.3390/md11061920
Article

Perna canaliculus Lipid Complex PCSO-524™ Demonstrated Pain Relief for Osteoarthritis Patients Benchmarked against Fish Oil, a Randomized Trial, without Placebo Control

, *  and
Clinic of Rheumatology and Internal Medicine, Academic Clinical Hospital, Wroclaw 50-556, Poland
* Author to whom correspondence should be addressed.
Received: 20 March 2013 / Revised: 8 May 2013 / Accepted: 21 May 2013 / Published: 5 June 2013
(This article belongs to the Special Issue Marine Compounds and Inflammation)
View Full-Text   |   Download PDF [400 KB, uploaded 24 February 2015]   |   Browse Figures

Abstract

Osteoarthritis (OA) typically generates pain, reduced mobility and reduced quality of life. Most conventional treatments for osteoarthritis, such as non-steroidal anti-inflammatory drugs (NSAIDs) and simple analgesics, have side effects. PCSO-524™, a non polar lipid extract from the New Zealand Green Lipped Mussel, is rich in omega-3 fatty acids and has been shown to reduce inflammation in both animal studies and patient trials. This OA trial examined pain relief changes in relation to quality of life and safety of use for OA patients who took PCSO-524™ compared with patients who took fish oil (containing an industry standard EPA-18% and DHA-12% blend). PCSO-524™ patients showed a statistically significant improvement compared with patients who took fish oil. There was an 89% decrease in their pain symptoms and 91% reported an improved quality of life. Patients treated with fish oil showed significantly less improvement and a greater level of physical discomfort during the study. These results suggest that PCSO-524™ might offer a potential alternative complementary therapy with no side effects for OA patients.
Keywords: Perna canaliculus; PCSO-524™; Lyprinol®; greenlipped mussel; osteoarthritis; arthritis; fish oil; pain relief; joint pain Perna canaliculus; PCSO-524™; Lyprinol®; greenlipped mussel; osteoarthritis; arthritis; fish oil; pain relief; joint pain
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Zawadzki, M.; Janosch, C.; Szechinski, J. Perna canaliculus Lipid Complex PCSO-524™ Demonstrated Pain Relief for Osteoarthritis Patients Benchmarked against Fish Oil, a Randomized Trial, without Placebo Control. Mar. Drugs 2013, 11, 1920-1935.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert